Delving into the Latest Updates on NBL-012 with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

Target

IL-23p19

Mechanism

IL-23p19 inhibitors(Interleukin-23 subunit p19 inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesDigestive System Disorders+ [2]

Active Indication

Hidradenitis SuppurativaPsoriasisInflammatory Bowel Diseases

Inactive Indication-

Originator Organization-

Active Organization

Novarock Biotherapeutics Ltd.

CSPC Pharmaceutical Group Ltd.

Inactive Organization

Shanghai Xinshi Biomedical Co., Ltd.

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

主要目的：评价NBL-012在中国健康受试者中单次皮下注射给药的安全性和耐受性。次要目的： 1.评价NBL-012在中国健康受试者中单次皮下注射给药的药代动力学（PK）特征。 2.评价NBL-012在中国健康受试者中单次皮下注射给药的免疫原性。 3.评价NBL-012在中国健康受试者中单次皮下注射给药的药效动力学（PD）特征。

[Translation]

Primary objective: To evaluate the safety and tolerability of a single subcutaneous injection of NBL-012 in healthy Chinese subjects. Secondary objectives: 1. To evaluate the pharmacokinetic (PK) characteristics of a single subcutaneous injection of NBL-012 in healthy Chinese subjects. 2. To evaluate the immunogenicity of a single subcutaneous injection of NBL-012 in healthy Chinese subjects. 3. To evaluate the pharmacodynamic (PD) characteristics of a single subcutaneous injection of NBL-012 in healthy Chinese subjects.

Start Date28 Jun 2021

Sponsor / Collaborator

Shanghai Xinshi Biomedical Co., Ltd.

100 Clinical Results associated with NBL-012

Login to view more data

100 Translational Medicine associated with NBL-012

Login to view more data

100 Patents (Medical) associated with NBL-012

Login to view more data

100 Deals associated with NBL-012

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hidradenitis Suppurativa	Phase 1	-	Novarock Biotherapeutics Ltd.	-
Inflammatory Bowel Diseases	Phase 1	-	Novarock Biotherapeutics Ltd.	-
Psoriasis	Phase 1	-	Novarock Biotherapeutics Ltd.	-